Tanja Lucke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2139388/publications.pdf Version: 2024-02-01



TANIA LUCKE

#	Article	IF	CITATIONS
1	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Scientific Reports, 2022, 12, 1435.	3.3	8
2	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	2.3	5
3	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respiratory Medicine, 2020, 172, 106117.	2.9	4
4	<p>Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort</p> . Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	1.8	10
5	Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respiratory Research, 2019, 20, 30.	3.6	26
6	Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 49, 123-129.	2.6	12
7	The revised GOLD 2017 COPD categorization in relation to comorbidities. Respiratory Medicine, 2018, 134, 79-85.	2.9	45
8	Medical Treatment of COPD. Deutsches Ärzteblatt International, 2018, 155, 599-605.	0.9	17
9	Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respiratory Research, 2017, 18, 14.	3.6	15
10	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	2.5	37
11	Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication. PLoS ONE, 2016, 11, e0163408.	2.5	40